Designed for Practical Clinical Use
Designed for Practical Clinical Use
Manufacturing & Delivery

Designed for Practical Clinical Use

Our development strategy focuses on a robust, cryopreserved cell therapy designed for practical handling, delivery and integration into future clinical workflows.

Scroll for More
Back to top

From Manufacturing to the Patient

For a cell therapy to reach patients, biological performance must be matched by a robust and practical product format. Corcellys is developing its therapy with manufacturing, cryopreservation, transport and clinical delivery considered as integral parts of the product from the beginning.

Our aim is to move beyond complex, site-dependent cell preparation toward a therapy that can ultimately be supplied in a standardized format and integrated into ophthalmic clinical practice.

A Cryopreserved, Ready-to-Use Strategy

Cryopreservation is central to our development approach. A cryopreserved product can separate manufacturing from the timing and location of treatment, enabling centralized production, quality control and distribution to clinical sites.

Our development strategy therefore focuses on:

  • Robust manufacturing — establishing reproducible processes capable of generating a consistent cell product.
  • Cryopreservation — preserving cell quality and function through freezing, storage and thawing.
  • Post-thaw performance — ensuring that cells retain the characteristics required for therapeutic use after recovery.
  • Practical delivery — developing a formulation and delivery approach compatible with ophthalmic procedures.
  • Product consistency — integrating analytical characterization and quality control throughout manufacturing.
  • Future scalability — designing processes with broader clinical deployment in mind.

Designed Around Clinical Reality

Cell therapies should not require highly specialized manufacturing capabilities at every hospital where patients are treated.

Our long-term objective is a product that can be manufactured and quality controlled centrally, stored and transported cryogenically, and prepared for administration at the clinical site through a practical and reproducible workflow.

This approach is intended to make regenerative cell therapy for the ocular surface not only biologically effective, but also practical to manufacture, distribute and ultimately deliver to patients.

.

Useful Links:

.

Last updated:
August 18, 2026
RESEARCH

OUR SCIENCE

Explore our science and therapeutic potential.

Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency

Limbal Stem Cell Deficiency

A Regenerative Cell Therapy for the Cornea
Our Cell Therapy

A Regenerative Cell Therapy for the Cornea

Building a Pipeline in Regenerative Ophthalmology
Beyond the Cornea

Building a Pipeline in Regenerative Ophthalmology

From Cell Biology to a Translatable Therapy
Translational Development

From Cell Biology to a Translatable Therapy

Our team. Building the Future of Cell Therapy
Our Team

Our team. Building the Future of Cell Therapy